Pathophysiological amyloid concentrations induce sustained upregulation of readthrough acetylcholinesterase mediating anti-apoptotic effects

Neuroscience

Volumn 240, Issue , 2013, Pages 349-360

  Li, G ^a   Klein, J ^a   Zimmermann, M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Acetylcholinesterase; Alternative splicing; Amyloid beta; ATP; Cholinergic plasticity; Neurotoxicity

Indexed keywords

ACETYLCHOLINESTERASE; ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN[1-42]; CASPASE 3; CHOLINE ACETYLTRANSFERASE; LACTATE DEHYDROGENASE; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CELL ACTIVITY; CELL SURVIVAL; CELL VIABILITY; CHOLINE UPTAKE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME RELEASE; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROPATHOLOGY; NEUROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; UPREGULATION;

ACETYLCHOLINESTERASE; ADENOSINE TRIPHOSPHATE; AMYLOID BETA-PEPTIDES; APOPTOSIS; CELL LINE, TUMOR; CHOLINE; CHOLINE O-ACETYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; L-LACTATE DEHYDROGENASE; NEUROBLASTOMA; TIME FACTORS; UP-REGULATION;

EID: 84876735268     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.02.040     Document Type: Article

References (82)

1. Abramov E., Dolev I., Fogel H., Ciccotosto G.D., Ruff E., Slutsky I. Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 2009, 12:1567-1576.
2. Alberdi E., Sanchez-Gomez M.V., Cavaliere F., Perez-Samartin A., Zugaza J.L., Trullas R., Domercq M., Matute C. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 2010, 47:264-272.
3. Arendt T., Bruckner M.K., Lange M., Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem Int 1992, 21:381-396.
4. Auld D.S., Kornecook T.J., Bastianetto S., Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002, 68:209-245.
5. Bartolini G., Orlandi M., Ammar K., Magrini E., Ferreri A.M., Rocchi P. Effect of a new derivative of retinoic acid on proliferation and differentiation in human neuroblastoma cells. Anticancer Res 2003, 23:1495-1499.
6. Ben Shaul Y., Benmoyal-Segal L., Ben Ari S., Bergman H., Soreq H. Adaptive acetylcholinesterase splicing patterns attenuate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Eur J Neurosci 2006, 23:2915-2922.
7. Berson A., Knobloch M., Hanan M., Diamant S., Sharoni M., Schuppli D., Geyer B.C., Ravid R., Mor T.S., Nitsch R.M., Soreq H. Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology. Brain 2008, 131:109-119.
8. Bielarczyk H., Tomaszewicz M., Madziar B., Cwikowska J., Pawelczyk T., Szutowicz A. Relationships between cholinergic phenotype and acetyl-CoA level in hybrid murine neuroblastoma cells of septal origin. J Neurosci Res 2003, 73:717-721.
9. Bodles A.M., Guthrie D.J., Harriott P., Campbell P., Irvine G.B. Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. Eur J Biochem 2000, 267:2186-2194.
10. Carson K.A., Geula C., Mesulam M.M. Electron microscopic localization of cholinesterase activity in Alzheimer brain tissue. Brain Res 1991, 540:204-208.
11. Chiti F., Webster P., Taddei N., Clark A., Stefani M., Ramponi G., Dobson C.M. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci U S A 1999, 96:3590-3594.
12. Chowdhury I., Tharakan B., Bhat G.K. Current concepts in apoptosis: the physiological suicide program revisited. Cell Mol Biol Lett 2006, 11:506-525.
13. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983, 219:1184-1190.
14. Crouch S.P., Kozlowski R., Slater K.J., Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods 1993, 160:81-88.
15. Cummings J.L., Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998, 6:S64-S78.
16. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Bennett D.A., Cochran E.J., Kordower J.H., Mufson E.J. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002, 51:145-155.
17. Dhitavat S., Ortiz D., Shea T.B., Rivera E.R. Acetyl-l-carnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels. Neurochem Res 2002, 27:501-505.
18. Dori A., Soreq H. ARP, the cleavable C-terminal peptide of " readthrough" acetylcholinesterase, promotes neuronal development and plasticity. J Mol Neurosci 2006, 28:247-255.
19. Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease - an update. Curr Alzheimer Res 2007, 4:577-580.
20. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999, 66:137-147.
21. Garcia-Ayllon M.S., Small D.H., Avila J., Saez-Valero J. Revisiting the role of acetylcholinesterase in Alzheimer's disease: cross-talk with P-tau and beta-amyloid. Front Mol Neurosci 2011, 4:22.
22. Geula C., Mesulam M.M. Cholinergic systems and related neuropathological predilections patterns in Alzheimer disease. Alzheimer disease 1994, 263-291. Raven Press, New York. R.D. Terry, R. Katzman, K.L. Bick (Eds.).
23. Giacobini E. Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry 2003, 18:S1-S5.
24. Greenberg D.S., Toiber D., Berson A., Soreq H. Acetylcholinesterase variants in Alzheimer's disease: from neuroprotection to programmed cell death. Neurodegener Dis 2010, 7:60-63.
25. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
26. Härtl R., Gleinich A., Zimmermann M. Dramatic increase in readthrough acetylcholinesterase in a cellular model of oxidative stress. J Neurochem 2011, 116:1088-1096.
27. Hartmann J., Erb C., Ebert U., Baumann K.H., Popp A., Konig G., Klein J. Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice. Neuroscience 2004, 125:1009-1017.
28. Hashemi S.H., Li J.Y., Ahlman H., Dahlstrom A. SSR2(a) receptor expression and adrenergic/cholinergic characteristics in differentiated SH-SY5Y cells. Neurochem Res 2003, 28:449-460.
29. Hoshi M., Takashima A., Murayama M., Yasutake K., Yoshida N., Ishiguro K., Hoshino T., Imahori K. Nontoxic amyloid beta peptide 1-42 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer's disease. J Biol Chem 1997, 272:2038-2041.
30. Hu W., Gray N.W., Brimijoin S. Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J Neurochem 2003, 86:470-478.
31. Inestrosa N.C., Alvarez A., Perez C.A., Moreno R.D., Vicente M., Linker C., Casanueva O.I., Soto C., Garrido J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996, 16:881-891.
32. Inestrosa N.C., Dinamarca M.C., Alvarez A. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. FEBS J 2008, 275:625-632.
33. Jope R.S. High affinity choline transport and acetylCoA production in brain and their roles in the regulation of acetylcholine synthesis. Brain Res 1979, 180:313-344.
34. Kar S., Issa A.M., Seto D., Auld D.S., Collier B., Quirion R. Amyloid beta-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J Neurochem 1998, 70:2179-2187.
35. Kar S., Seto D., Gaudreau P., Quirion R. Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. J Neurosci 1996, 16:1034-1040.
36. Kaufer D., Friedman A., Seidman S., Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998, 393:373-377.
37. Keil U., Bonert A., Marques C.A., Scherping I., Weyermann J., Strosznajder J.B., Muller-Spahn F., Haass C., Czech C., Pradier L., Muller W.E., Eckert A. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem 2004, 279:50310-50320.
38. Kraveka J.M., Li L., Bielawski J., Obeid L.M., Ogretmen B. Involvement of endogenous ceramide in the inhibition of telomerase activity and induction of morphologic differentiation in response to all-trans-retinoic acid in human neuroblastoma cells. Arch Biochem Biophys 2003, 419:110-119.
39. Kristensen S.R. A critical appraisal of the association between energy charge and cell damage. Biochim Biophys Acta 1989, 1012:272-278.
40. Kuhar M.J., Murrin L.C. Sodium-dependent, high affinity choline uptake. J Neurochem 1978, 30:15-21.
41. Kurz C., Ungerer I., Lipka U., Kirr S., Schutt T., Eckert A., Leuner K., Muller W.E. The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptide. Br J Pharmacol 2010, 160:246-257.
42. Layer P.G. Nonclassical roles of cholinesterases in the embryonic brain and possible links to Alzheimer disease. Alzheimer Dis Assoc Disord 1995, 9(Suppl. 2):29-36.
43. Li B., Stribley J.A., Ticu A., Xie W., Schopfer L.M., Hammond P., Brimijoin S., Hinrichs S.H., Lockridge O. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J Neurochem 2000, 75:1320-1331.
44. Li G., Gleinich A., Lau H., Zimmermann M. Staurosporine-induced apoptosis presents with unexpected cholinergic effects in a differentiated neuroblastoma cell line. Neurochem Int 2012, 61:1011-1020.
45. Li R., Lindholm K., Yang L.B., Yue X., Citron M., Yan R., Beach T., Sue L., Sabbagh M., Cai H., Wong P., Price D., Shen Y. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A 2004, 101:3632-3637.
46. Massoulie J., Bon S., Perrier N., Falasca C. The C-terminal peptides of acetylcholinesterase: cellular trafficking, oligomerization and functional anchoring. Chem Biol Interact 2005, 157-158:3-14.
47. Meerson A., Cacheaux L., Goosens K.A., Sapolsky R.M., Soreq H., Kaufer D. Changes in brain MicroRNAs contribute to cholinergic stress reactions. J Mol Neurosci 2010, 40:47-55.
48. Meshorer E., Bryk B., Toiber D., Cohen J., Podoly E., Dori A., Soreq H. SC35 promotes sustainable stress-induced alternative splicing of neuronal acetylcholinesterase mRNA. Mol Psychiatry 2005, 10:985-997.
49. Mor I., Sklan E.H., Podoly E., Pick M., Kirschner M., Yogev L., Bar-Sheshet I.S., Schreiber L., Geyer B., Mor T., Grisaru D., Soreq H. Acetylcholinesterase-R increases germ cell apoptosis but enhances sperm motility. J Cell Mol Med 2008, 12:479-495.
50. Mufson E.J., Counts S.E., Perez S.E., Ginsberg S.D. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother 2008, 8:1703-1718.
51. Novakova J., Mikasova L., Machova E., Lisa V., Dolezal V. Chronic treatment with amyloid beta(1-42) inhibits non-cholinergic high-affinity choline transport in NG108-15 cells through protein kinase C signaling. Brain Res 2005, 1062:101-110.
52. Pahlman S., Hoehner J.C., Nanberg E., Hedborg F., Fagerstrom S., Gestblom C., Johansson I., Larsson U., Lavenius E., Ortoft E. Differentiation and survival influences of growth factors in human neuroblastoma. Eur J Cancer 1995, 31A:453-458.
53. Pahlman S., Ruusala A.I., Abrahamsson L., Mattsson M.E., Esscher T. Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. Cell Differ 1984, 14:135-144.
54. Papassotiropoulos A., Streffer J.R., Tsolaki M., Schmid S., Thal D., Nicosia F., Iakovidou V., Maddalena A., Lutjohann D., Ghebremedhin E., Hegi T., Pasch T., Traxler M., Bruhl A., Benussi L., Binetti G., Braak H., Nitsch R.M., Hock C. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 2003, 60:29-35.
55. Pearson H.A., Peers C. Physiological roles for amyloid beta peptides. J Physiol 2006, 575:5-10.
56. Pedersen W.A., Kloczewiak M.A., Blusztajn J.K. Amyloid beta-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A 1996, 93:8068-8071.
57. Piaceri I., Rinnoci V., Bagnoli S., Failli Y., Sorbi S. Mitochondria and Alzheimer's disease. J Neurol Sci 2012, 322:31-34.
58. Poongodi G.L., Suresh N., Gopinath S.C., Chang T., Inoue S., Inoue Y. Dynamic change of neural cell adhesion molecule polysialylation on human neuroblastoma (IMR-32) and rat pheochromocytoma (PC-12) cells during growth and differentiation. J Biol Chem 2002, 277:28200-28211.
59. Rees T., Hammond P.I., Soreq H., Younkin S., Brimijoin S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging 2003, 24:777-787.
60. Rees T.M., Berson A., Sklan E.H., Younkin L., Younkin S., Brimijoin S., Soreq H. Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. Curr Alzheimer Res 2005, 2:291-300.
61. Ronowska A., Dys A., Jankowska-Kulawy A., Klimaszewska-Lata J., Bielarczyk H., Romianowski P., Pawelczyk T., Szutowicz A. Short-term effects of zinc on acetylcholine metabolism and viability of SN56 cholinergic neuroblastoma cells. Neurochem Int 2010, 56:143-151.
62. Sabate R., Espargaro A., de Groot N.S., Valle-Delgado J.J., Fernandez-Busquets X., Ventura S. The role of protein sequence and amino acid composition in amyloid formation: scrambling and backward reading of IAPP amyloid fibrils. J Mol Biol 2010, 404:337-352.
63. Sberna G., Saez-Valero J., Beyreuther K., Masters C.L., Small D.H. The amyloid beta-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. J Neurochem 1997, 69:1177-1184.
64. Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011, 221:555-563.
65. Shewmaker F., Ross E.D., Tycko R., Wickner R.B. Amyloids of shuffled prion domains that form prions have a parallel in-register beta-sheet structure. Biochemistry 2008, 47:4000-4007.
66. Simakova O., Arispe N.J. The cell-selective neurotoxicity of the Alzheimer's Abeta peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane binding is required for Abeta toxicity. J Neurosci 2007, 27:13719-13729.
67. Sinha M., Behera P., Bhowmick P., Banerjee K., Basu S., Chakrabarti S. Aging promotes amyloid-beta peptide induced mitochondrial dysfunctions in rat brain: a molecular link between aging and Alzheimer's disease. J Alzheimers Dis 2011, 27:753-765.
68. Siow N.L., Xie H.Q., Choi R.C., Tsim K.W. ATP induces the post-synaptic gene expression in neuron-neuron synapses: transcriptional regulation of AChE catalytic subunit. Chem Biol Interact 2005, 157-158:423-426.
69. Slotkin T.A., Nemeroff C.B., Bissette G., Seidler F.J. Overexpression of the high affinity choline transporter in cortical regions affected by Alzheimer's disease. Evidence from rapid autopsy studies. J Clin Invest 1994, 94:696-702.
70. Stine W.B., Dahlgren K.N., Krafft G.A., LaDu M.J. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 2003, 278:11612-11622.
71. Szutowicz A., Tomaszewicz M., Jankowska A., Madziar B., Bielarczyk H. Acetyl-CoA metabolism in cholinergic neurons and their susceptibility to neurotoxic inputs. Metab Brain Dis 2000, 15:29-44.
72. Tiong C.X., Lu M., Bian J.S. Protective effect of hydrogen sulphide against 6-OHDA-induced cell injury in SH-SY5Y cells involves PKC/PI3K/Akt pathway. Br J Pharmacol 2010, 161:467-480.
73. Toiber D., Berson A., Greenberg D., Melamed-Book N., Diamant S., Soreq H. N-acetylcholinesterase-induced apoptosis in Alzheimer's disease. PLoS One 2008, 3:e3108.
74. Tomic J.L., Pensalfini A., Head E., Glabe C.G. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 2009, 35:352-358.
75. Wakshlag J.J., Antonyak M.A., Boehm J.E., Boehm K., Cerione R.A. Effects of tissue transglutaminase on beta -amyloid1-42-induced apoptosis. Protein J 2006, 25:83-94.
76. Winkler J., Connor D.J., Frautschy S.A., Behl C., Waite J.J., Cole G.M., Thal L.J. Lack of long-term effects after beta-amyloid protein injections in rat brain. Neurobiol Aging 1994, 15:601-607.
77. Xie H.R., Hu L.S., Li G.Y. SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin Med J (Engl) 2010, 123:1086-1092.
78. Yankner B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990, 250:279-282.
79. Zimmerman G., Soreq H. Readthrough acetylcholinesterase: a multifaceted inducer of stress reactions. J Mol Neurosci 2006, 30:197-200.
80. Zimmermann M., Gardoni F., Marcello E., Colciaghi F., Borroni B., Padovani A., Cattabeni F., Di Luca M. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem 2004, 90:1489-1499.
81. Zimmermann M., Grosgen S., Westwell M.S., Greenfield S.A. Selective enhancement of the activity of C-terminally truncated, but not intact, acetylcholinesterase. J Neurochem 2008, 104:221-232.
82. Zimmermann M., Westwell M.S., Greenfield S.A. Impact of detergents on the activity of acetylcholinesterase and on the effectiveness of its inhibitors. Biol Chem 2009, 390:19-26.